CTRP3 and Progranulin in Patients With Coronary Artery Disease

Completed

• Conditions: Coronary Artery Disease

• Registration Number: NCT01869816
• Lead Sponsor: Korea University

Brief Summary

Visceral obesity is the one of the major causes of cardiovascular morbidity and mortality in industrialized countries. Adipose tissue secretes various kinds of bioactive molecules termed adipokines which contribute to the development of obesity-related disorders including cardiovascular disease (CVD). Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to compare circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well-known CAD risk factors.

Detailed Description

CTRP-3 (synonyms CORS-26, cartducin and cartonectin) is a potent anti-inflammatory adipokine that inhibits proinflammatory pathways in monocytes and adipocytes. Using a recently developed enzymelinked immunosorbent assay (ELISA), we reported that circulating CTRP-3 levels were elevated in patients with glucose metabolism dysregulation.

Progranulin was identified as a key adipokine mediating high fat diet-induced insulin resistance and obesity through interleukin-6 (IL-6) in adipose tissue. We previously reported that progranulin levels were significantly higher in individuals with type 2 diabetes and were associated with macrophage infiltration in omental adipose tissue. Moreover, the expression of progranulin reduces inflammation and its degradation into granulins peptides enhances inflammation in atherosclerotic plaque, which may contribute to the progression of atherosclerosis There has been no previous report on the implication of CTRP-3 or progranulin in humans with cardiovascular disease (CAD). In the present study, we compared circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well known CAD risk factors.

Study Timeline

• Study Start: 2011-03-01
• Primary Completion: 2012-12-31
• Study Completion: 2012-12-31
• Study First Submitted: 2013-06-02
• Study First Submitted QC: 2013-06-02
• Study First Posted: 2013-06-05
• Status Verified: 2020-08
• Last Update Submitted: 2020-08-31
• Last Update Posted: 2020-09-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 362

Inclusion Criteria

• acute myocardial infarction
• unstable angina
• stable angina pectoris

Exclusion Criteria

For control group, we exclude the participants who had

• a history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
• type 2 diabetes
• stage 2 hypertension (resting blood pressure, ≥160/100 mmHg)
• malignancy
• severe renal or hepatic disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CTRP3	16 months	CTRP3 (ng/ml)

Secondary Outcome Measures

Name	Time	Method
LDL cholesterol	16 months	LDL (mg/dl)
hsCRP	16 months	hsCRP (mg/dl)
creatinine	16 months	creatinine (mg/dl)
SBP	16 months	SBP (mmHg)

Trial Locations

Locations (1)

Korea University Guro Hospital Dept. of Endocrinology; 🇰🇷 Seoul, Korea, Republic of